Medidata Solutions Introduces Unique Site Visit Reporting Capability within EDC/CDM Software
New Tool Further Improves Productivity of Clinical Study Monitors and Enhances Cross-Study Operational Visibility for Study Managers
Medidata Solutions Introduces Unique Site Visit Reporting Capability within EDC/CDM Software
Medidata Solutions , a leading global provider of hosted clinical development solutions, today announced the introduction of Rave Monitor, an extension to its electronic data capture (EDC) and clinical data management (CDM) solution, Medidata Rave® . Rave Monitor offers innovative visit report functionality as an integral part of the EDC/CDM system, providing research sponsors and contract research organizations (CROs) with a more efficient, compliant and cost-effective way to manage site visits.
Site monitoring activities represent one of the largest cost drivers in clinical research today. To sponsors and CROs, this raises the importance of improving the efficiency and effectiveness with which monitors or clinical research associates (CRAs) perform tasks – such as ensuring site compliance, resolving site issues and helping sites provide accurate data quickly for analysis – to a strategic level. By providing tools to automate edit-checking, remotely query sites’ data entries and accelerate source data verification, single EDC/CDM solutions such as Medidata Rave have significantly improved monitors’ ability to work with sites to expedite the availability of clean data. Rave Monitor now further extends the set of capabilities available to CRAs by providing a new tool that makes a key part of their job – reporting on-site visits –– more efficient, as well.
“Implementing a solution to manage site visit reports from within Rave makes good business sense to us,” said Wendy Morahan, Lead Clinical Systems Analyst, Array BioPharma. “Medidata’s Rave Monitor leverages our core enterprise software investments; monitors can hit the ground running with the tool because they already use Rave on a regular basis, and making changes to report forms is as simple as editing case report forms (CRFs).”
Rave Monitor provides users with online and offline visit report capture, approval workflow and inter-study and cross-study status reporting – all within the context of their existing Rave deployment. This means that monitors who are familiar with Rave through other activities can use the tool with minimal training. Also, unlike many standalone or homegrown solutions for visit reporting, Monitor builds upon Rave’s powerful workflow management, reporting and audit capabilities and supports integration with other clinical systems such as Clinical Trials Management Systems (CTMS).
“Medidata Rave already provides great value to study monitors in our clinical trials,” said Sinikka Vähä-Ojala, Study Operation Manager, Orion Pharma. “The addition of new modules like Rave Monitor shows that Medidata is focused on providing sponsors with ways to further enhance operational efficiency and visibility where it counts the most, in ways that go beyond traditional EDC offerings.”
Rave Monitor assists in increasing CRAs’ productivity by allowing them to directly incorporate EDC data into their offline forms during visits and while completing their reports. Report approval and visit milestones are expedited through automated workflow management, electronic signatures, task dashboards and email notifications. Study managers have access to ad-hoc reports that give them improved visibility into visit status, top issues raised at site visits and more – within and across studies.
“The introduction of Rave Monitor enables us to provide research sponsors and CROs with even more ways to work effectively with their sites and measure that effectiveness across studies,” said Glen de Vries, President of Medidata Solutions. “Medidata is committed to enhancing our customers’ competitive advantage by providing the tools and services that enable operational excellence across their entire clinical development team.”
Rave Monitor will be demonstrated later this month in Boston, Mass. at the Bio-IT World Conference and Expo, and in Orlando, Fla. at the IIR EDC & Beyond conference. It will be offered as an additional module for Rave version 5.6.3.
About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com ) is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer™), investigator benchmarking and budgeting (Medidata Grants Manager™), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor™), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave®). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Lois Paul & Partners
Susan McCarron, 781-782-5767
Susan_McCarron@lpp.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FES Super Extends Partnership with SS&C28.5.2025 00:13:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 21:48:00 CEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom